Weighing the pros and cons of early delivery in women with preeclampsia
Planned delivery or expectant management in preeclampsia: an individual participant data meta-analysis
Delivery of the baby and the placenta is still the only definitive management for preeclampsia, and planned delivery is recommended for all women with preeclampsia who are 37 weeks pregnant or more. However, for women who are 34-36 weeks pregnant with preeclampsia, immediate delivery is not recommended due to the risks it may present to the baby. Healthcare providers will typically follow “expectant management” for these women, monitoring them closely until delivery is necessary because of possible risks for the baby from early preterm birth. Several smaller studies have explored this recommendation for expectant management, asking whether planned delivery among women with preeclampsia between 34-36 weeks of pregnancy is more beneficial for mother and baby compared to expectant management. In this study, researchers combined the data from several of these studies (1,790 participants across six different research studies) in a meta-analysis to ask if planned delivery between 34-36 weeks of pregnancy in women with preeclampsia can reduce complications for the mother and her baby. Researchers created a composite outcome to answer their question, a combination of several possible clinical complications related to preeclampsia and early delivery.
The results showed that planned delivery (compared to “expectant management”) at 34 weeks or later reduced risk for complications in the mother as well as the decreased the likelihood the baby would be small for their gestational age. However, planned early delivery was found to increase the risk for short-term respiratory complications in the baby.
Take home message: This meta-analysis showed that planned delivery in women 34-36 weeks pregnant with preeclampsia has both benefits and risks. These risks and benefits should be consider by clinicians caring for women with preeclampsia and discussed with patients when presenting management options for her pregnancy.
Link: https://www.ajog.org/article/S0002-9378(22)00315-5/fulltext
Citation: Beardmore-Gray A, Seed PT, Fleminger J, Zwertbroek E, Bernardes T, Mol BW, Battersby C, Koopmans C, Broekhuijsen K, Boers K, Owens MY, Thornton J, Green M, Shennan AH, Groen H, Chappell LC. Planned delivery or expectant management in preeclampsia: an individual participant data meta-analysis. Am J Obstet Gynecol. 2022 Apr 26:S0002-9378(22)00315-5. doi: 10.1016/j.ajog.2022.04.034. Epub ahead of print. PMID: 35487323.
About Research Roundup
Each quarter, our team of researchers reviews the most current studies related to hypertensive disorders of pregnancy and selects those studies they feel will be of greatest interest to our community to summarize.
Special thanks to our volunteer research team, who under the leadership of Dr. Elizabeth Sutton, make Research Roundup possible: Alisse Hauspurg, MD Felicia LeMoine, and MD Jenny Sones, PhD, DVM.
Related Articles
Hypertensive disorders of pregnancy significantly increase your risk of developing long-term heart problems. A careful review of blood pressure elevations during and after pregnancy may assist in iden...
Hypertensive disorders of pregnancy (HDP) can affect different groups of women in different ways, and even though we know this happening, we don't fully understand why. There are many factors, like bi...
There is growing evidence that studies examining pregnancy and its complications need to start early within the pregnancy to fully understand the nature of preeclampsia. Key gestational milestones, wh...
It is known that chronic hypertension and high BMI (body mass index) are risk factors for hypertensive disorders of pregnancy (HDP). Studies documenting this risk have usually assessed blood pre...
Several biomarker tests are under development to predict or diagnose preeclampsia. While none of these tests are yet widely accepted in U.S. clinical practice, two FDA-approved tests are available in...